CANDEL THERAPEUTICS, INC. Stock-Based Compensation
CANDEL THERAPEUTICS, INC. (CADL) reported Stock-Based Compensation of $4.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.86M, a 172.19% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.45M, a 362.42% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.29M, a 3.70% increase year-over-year.
- CANDEL THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.16M, a 1.77% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $3.82M, a 28.14% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $5.31M, a 71.85% increase from fiscal 2023.
- CANDEL THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $3.09M, a 33.98% increase from fiscal 2022.
- CANDEL THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $2.31M, a 22.14% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.31M 10-Q · filed 2026-08-13 | $5.60M derived: sum of 3 quarters · filed 2026-08-13 | $6.76M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.45M 10-Q · filed 2026-05-14 | $2.74M derived: sum of 2 quarters · filed 2026-05-14 | $3.90M derived: sum of 3 quarters · filed 2026-05-14 | $4.96M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.45M derived: sum of 2 quarters · filed 2026-03-12 | $3.50M derived: sum of 3 quarters · filed 2026-08-13 | $3.82M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.21M derived: sum of 2 quarters · filed 2026-08-13 | $2.53M 10-Q · filed 2025-11-13 | $3.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.36M 10-Q · filed 2026-08-13 | $2.61M derived: sum of 3 quarters · filed 2026-08-13 | $3.79M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $314.00K 10-Q · filed 2026-05-14 | $1.56M derived: sum of 2 quarters · filed 2026-05-14 | $2.74M derived: sum of 3 quarters · filed 2026-05-14 | $4.58M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.43M derived: sum of 2 quarters · filed 2026-03-12 | $4.27M derived: sum of 3 quarters · filed 2026-03-12 | $5.31M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.02M derived: sum of 2 quarters · filed 2025-11-13 | $4.07M 10-Q · filed 2025-11-13 | $5.01M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.88M 10-Q · filed 2025-08-14 | $3.82M derived: sum of 3 quarters · filed 2025-08-14 | $4.51M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.04M 10-Q · filed 2025-05-13 | $1.98M derived: sum of 2 quarters · filed 2025-05-13 | $2.67M derived: sum of 3 quarters · filed 2025-05-13 | $3.40M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $939.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.63M derived: sum of 2 quarters · filed 2025-03-13 | $2.36M derived: sum of 3 quarters · filed 2025-03-13 | $3.09M 10-K · filed 2025-03-13 |
| 2023-09-30 | $686.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.42M derived: sum of 2 quarters · filed 2024-11-14 | $2.15M 10-Q · filed 2024-11-14 | $2.79M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $733.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.47M 10-Q · filed 2024-08-13 | $2.10M derived: sum of 3 quarters · filed 2024-08-13 | $2.84M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $733.00K 10-Q · filed 2024-05-14 | $1.37M derived: sum of 2 quarters · filed 2024-05-14 | $2.11M derived: sum of 3 quarters · filed 2024-05-14 | $2.55M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $634.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.38M derived: sum of 2 quarters · filed 2024-03-28 | $1.81M derived: sum of 3 quarters · filed 2024-03-28 | $2.31M 10-K · filed 2024-03-28 |
| 2022-09-30 | $743.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.18M derived: sum of 2 quarters · filed 2023-11-09 | $1.67M 10-Q · filed 2023-11-09 | $1.23M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $438.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $930.00K 10-Q · filed 2023-08-10 | $484.00K derived: sum of 3 quarters · filed 2023-08-10 | $2.39M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $492.00K 10-Q · filed 2023-05-11 | $46.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.96M derived: sum of 3 quarters · filed 2023-05-11 | $3.02M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.46M derived: sum of 2 quarters · filed 2023-03-30 | $2.53M derived: sum of 3 quarters · filed 2023-03-30 | $2.96M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.98M derived: sum of 2 quarters · filed 2022-11-10 | $3.41M 10-Q · filed 2022-11-10 | $5.16M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $1.50M 10-Q · filed 2022-08-05 | $3.25M derived: sum of 3 quarters · filed 2022-08-05 | $3.34M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $431.00K 10-Q · filed 2022-05-12 | $2.18M derived: sum of 2 quarters · filed 2022-05-12 | $2.27M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.84M derived: sum of 2 quarters · filed 2022-03-29 | $2.11M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $354.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $271.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |